ENILLORING Drug Patent Profile
✉ Email this page to a colleague
When do Enilloring patents expire, and when can generic versions of Enilloring launch?
Enilloring is a drug marketed by Xiromed and is included in one NDA.
The generic ingredient in ENILLORING is ethinyl estradiol; etonogestrel. There are twenty-six drug master file entries for this compound. Ten suppliers are listed for this compound. Additional details are available on the ethinyl estradiol; etonogestrel profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Enilloring
A generic version of ENILLORING was approved as ethinyl estradiol; etonogestrel by TEVA PHARMS USA INC on January 13th, 2021.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for ENILLORING?
- What are the global sales for ENILLORING?
- What is Average Wholesale Price for ENILLORING?
Summary for ENILLORING
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 3 |
| Drug Prices: | Drug price information for ENILLORING |
| DailyMed Link: | ENILLORING at DailyMed |
Pharmacology for ENILLORING
| Drug Class | Estrogen Progestin |
| Mechanism of Action | Estrogen Receptor Agonists |
US Patents and Regulatory Information for ENILLORING
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Xiromed | ENILLORING | ethinyl estradiol; etonogestrel | RING;VAGINAL | 211157-001 | Jun 29, 2023 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
